Market Cap 146.48B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.37
Forward PE 8.58
Profit Margin 12.42%
Debt to Equity Ratio 0.71
Volume 45,241,917
Avg Vol 34,969,270
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 34%
Beta 0.34
Analysts Sell
Price Target $29.28

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
simonds
simonds Jun. 11 at 10:17 PM
$PFE Going back below $25.50?
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Jun. 11 at 10:11 PM
$PFE So say we finally get back to 30. What's everyone doing? I can't decide if I will stay disciplined and stay the course or put an end to the years of dealing with the market hating my biggest position. Im leaning towards staying but when it inevitably drops back to 26 in a week im going to be kicking myself yet again.
1 · Reply
RunnerSignals
RunnerSignals Jun. 11 at 8:20 PM
$BKH $PFE $DTIL $PIPR $TMO Wall Street Analyst Upgrades to Watch https://stocksrunner.com/news/2026-06-11-wall-street-analyst-upgrades-to-watch
0 · Reply
Quantumup
Quantumup Jun. 11 at 8:19 PM
Stifel on $ORIC said: We resume coverage of ORIC Pharmaceuticals with a Buy Rating and a $14 target price. $PFE $JNJ IPSEY DSNKY Stifel added—ORIC's lead asset, rinzimetostat, is a PRC2 complex inhibitor being developed in combination with darolutamide in metastatic castration resistant prostate cancer (mCRPC) — a Ph3 clinical trial (Himalayas-1) is expected to initiate in June/July 2026 in mCRPC patients previously treated with abiraterone. Logic for the combination is PRC2 inhibition blocks/reverts epigenetic reprogramming, resensitizing prostate cancer cells to androgen receptor pathway inhibitors (ARPIs) like darolutamide. ORIC has cash runway out to 2H28, getting them through Himalayas-1 top-line data expected in early 2028.
0 · Reply
Muhin
Muhin Jun. 11 at 8:02 PM
$PFE tom we open big!
1 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 11 at 7:55 PM
$PFE weak close as is tradition
0 · Reply
oak8912
oak8912 Jun. 11 at 7:41 PM
$PFE do you think it's a bad time for me to buy a few 30 strike calls?
1 · Reply
EquityClock
EquityClock Jun. 11 at 7:33 PM
Generating healthy returns in our pharmaceutical holdings today: optimal holding period between May 8th and September 6th. Pharma holdings have been the ideal offset to Tech volatility in recent days, keeping our return profile positive in both up and down market sessions so far this month. $IHE $PFE
0 · Reply
nimii
nimii Jun. 11 at 7:18 PM
$PFE gimme 28 plz
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 11 at 6:50 PM
$SLS $MRK $ABBV $PFE 4 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Pfizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth. REGAL Phase 3 data is about to deliver what incredible modeling has predicted, oncology may be about to witness the most consequential and contested acquisition it has seen in a generation. Prepare for Bidding War. ✌️🙏❤️‍🩹
0 · Reply
Latest News on PFE
Pfizer says FDA approves expanded indication for Hympavzi

2026-06-08T10:51:57.000Z - 3 days ago

Pfizer says FDA approves expanded indication for Hympavzi


US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 3 days ago

US FDA approves Pfizer's bleeding disorder drug for children


Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 5 days ago

Pfizer Transcript: Study update


Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 5 days ago

Pfizer Slides: Study update


Mailbag: A Follow-Up on Pfizer & Other Questions

May 30, 2026, 9:22 AM EDT - 12 days ago

Mailbag: A Follow-Up on Pfizer & Other Questions

AGNC LAND NLY PFFA


Guardant Health to present 38 abstracts at ASCO 2026 meeting

2026-05-28T12:35:12.000Z - 14 days ago

Guardant Health to present 38 abstracts at ASCO 2026 meeting

GH


Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:09 PM EDT - 5 weeks ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC


Pfizer CEO on AI-designed molecule, and race to use new tech

May 5, 2026, 4:02 PM EDT - 5 weeks ago

Pfizer CEO on AI-designed molecule, and race to use new tech


3 Dividend Stocks for May 2026

May 5, 2026, 11:30 AM EDT - 5 weeks ago

3 Dividend Stocks for May 2026

SYY WSO


Pfizer Earnings Call Transcript: Q1 2026

May 5, 2026, 10:00 AM EDT - 5 weeks ago

Pfizer Earnings Call Transcript: Q1 2026


Pfizer Earnings release: Q1 2026

May 5, 2026, 10:00 AM EDT - 5 weeks ago

Pfizer Earnings release: Q1 2026


Pfizer Quarterly report: Q1 2026

May 5, 2026, 10:00 AM EDT - 5 weeks ago

Pfizer Quarterly report: Q1 2026


Pfizer Slides: Q1 2026

May 5, 2026, 10:00 AM EDT - 5 weeks ago

Pfizer Slides: Q1 2026


Pfizer Posts Better-Than-Expected Revenue, Profit

May 5, 2026, 8:35 AM EDT - 5 weeks ago

Pfizer Posts Better-Than-Expected Revenue, Profit


Why selling these 3 dividend stocks could be a mistake

May 5, 2026, 7:05 AM EDT - 5 weeks ago

Why selling these 3 dividend stocks could be a mistake

EPD UPS


US FDA approves Pfizer, Arvinas' breast cancer drug

May 1, 2026, 12:37 PM EDT - 5 weeks ago

US FDA approves Pfizer, Arvinas' breast cancer drug

ARVN


Pfizer's blood cancer drug meets main goal in late-stage trial

Apr 29, 2026, 7:42 AM EDT - 6 weeks ago

Pfizer's blood cancer drug meets main goal in late-stage trial


Pfizer Reaches Three Settlement Agreements for VYNDAMAX

Apr 28, 2026, 10:17 AM EDT - 6 weeks ago

Pfizer Reaches Three Settlement Agreements for VYNDAMAX


Pfizer Transcript: AGM 2026

Apr 23, 2026, 9:00 AM EDT - 7 weeks ago

Pfizer Transcript: AGM 2026


Pfizer Declares Second-Quarter 2026 Dividend

Apr 22, 2026, 4:45 PM EDT - 7 weeks ago

Pfizer Declares Second-Quarter 2026 Dividend


Pfizer GLP-1 weight loss drug available for pre-order in China

Apr 22, 2026, 5:18 AM EDT - 7 weeks ago

Pfizer GLP-1 weight loss drug available for pre-order in China


The Big 3: PFE, V, SYF

Apr 16, 2026, 1:01 PM EDT - 2 months ago

The Big 3: PFE, V, SYF

SYF V


simonds
simonds Jun. 11 at 10:17 PM
$PFE Going back below $25.50?
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Jun. 11 at 10:11 PM
$PFE So say we finally get back to 30. What's everyone doing? I can't decide if I will stay disciplined and stay the course or put an end to the years of dealing with the market hating my biggest position. Im leaning towards staying but when it inevitably drops back to 26 in a week im going to be kicking myself yet again.
1 · Reply
RunnerSignals
RunnerSignals Jun. 11 at 8:20 PM
$BKH $PFE $DTIL $PIPR $TMO Wall Street Analyst Upgrades to Watch https://stocksrunner.com/news/2026-06-11-wall-street-analyst-upgrades-to-watch
0 · Reply
Quantumup
Quantumup Jun. 11 at 8:19 PM
Stifel on $ORIC said: We resume coverage of ORIC Pharmaceuticals with a Buy Rating and a $14 target price. $PFE $JNJ IPSEY DSNKY Stifel added—ORIC's lead asset, rinzimetostat, is a PRC2 complex inhibitor being developed in combination with darolutamide in metastatic castration resistant prostate cancer (mCRPC) — a Ph3 clinical trial (Himalayas-1) is expected to initiate in June/July 2026 in mCRPC patients previously treated with abiraterone. Logic for the combination is PRC2 inhibition blocks/reverts epigenetic reprogramming, resensitizing prostate cancer cells to androgen receptor pathway inhibitors (ARPIs) like darolutamide. ORIC has cash runway out to 2H28, getting them through Himalayas-1 top-line data expected in early 2028.
0 · Reply
Muhin
Muhin Jun. 11 at 8:02 PM
$PFE tom we open big!
1 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 11 at 7:55 PM
$PFE weak close as is tradition
0 · Reply
oak8912
oak8912 Jun. 11 at 7:41 PM
$PFE do you think it's a bad time for me to buy a few 30 strike calls?
1 · Reply
EquityClock
EquityClock Jun. 11 at 7:33 PM
Generating healthy returns in our pharmaceutical holdings today: optimal holding period between May 8th and September 6th. Pharma holdings have been the ideal offset to Tech volatility in recent days, keeping our return profile positive in both up and down market sessions so far this month. $IHE $PFE
0 · Reply
nimii
nimii Jun. 11 at 7:18 PM
$PFE gimme 28 plz
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 11 at 6:50 PM
$SLS $MRK $ABBV $PFE 4 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Pfizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth. REGAL Phase 3 data is about to deliver what incredible modeling has predicted, oncology may be about to witness the most consequential and contested acquisition it has seen in a generation. Prepare for Bidding War. ✌️🙏❤️‍🩹
0 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 11 at 6:31 PM
$PFE Albert this is when you buy some shares to fuel the momentum
3 · Reply
Quantumup
Quantumup Jun. 11 at 5:52 PM
H.C. Wainwright⬇️ $GPCR's PT to $70 (was $100) and reiterated at Buy $LLY $PFE AZN NVO VKTX H.C. Wainwright said: For aleniglipron, tolerability stays the key differentiator on the 2.5mg start, but absolute nausea/vomiting is class-typical, so persistence, not Gl burden might be more important for commercial success. However, from landscape point of view, retatrutide's clean low-dose profile and Pfizer's once-monthly injectable creates a new bar in the same mid-BMI market the orals are chasing. For a clear win, aleniglipron must prove efficacy durability above orforglipron and elecoglipron in a powered ITT population, low discontinuation on a faster titration, Gl burden below elecoglipron's, and substudy differentiation (body composition, SWITCH, T2D, cardiometabolic benefit) in the Phase 3. Therefore, given the competitive pressure from the emerging landscape, we are revisiting our penetration assumptions, which lowers our PT from $100 to $70.
0 · Reply
breakawayrider
breakawayrider Jun. 11 at 5:28 PM
$PFE pop and drop, same damn thing everytime
0 · Reply
Gj64
Gj64 Jun. 11 at 5:07 PM
$PFE RNGE https://www.fool.com/investing/2026/06/11/why-pfizer-stock-popped-today/
0 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 11 at 5:06 PM
$PFE genuinely the exact same chart every time we pop in the morning lol
2 · Reply
nimii
nimii Jun. 11 at 5:05 PM
$PFE 😤
0 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 11 at 4:49 PM
$PFE deflation 🫩
0 · Reply
Businesspro
Businesspro Jun. 11 at 4:14 PM
$PFE 🔥🚀🚀🚀🚀🚀 IMO start of a new uptrend confirmed Watching for continuation upwards Not expecting a fast move but I like the chart set up
0 · Reply
Dtt014
Dtt014 Jun. 11 at 3:51 PM
$PFE $27 tomorrow?
0 · Reply
JBS_84
JBS_84 Jun. 11 at 3:37 PM
$PFE hopefully 26.2 holds as support this time. After that we need 26.53 area. If 26.2 doesn't hold back to 25.73
1 · Reply
pineconecameo
pineconecameo Jun. 11 at 2:56 PM
$PFE $27 got me ready to paint ♻️
0 · Reply
BullMaven
BullMaven Jun. 11 at 2:56 PM
$PFE soon 30+
0 · Reply